DJ Carvolix: Results of the votes of the Combined Shareholders' General Meeting of January 30, 2026
Affluent Medical
Carvolix: Results of the votes of the Combined Shareholders' General Meeting of January 30, 2026
02-Feb-2026 / 07:30 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Results of the votes of the Combined Shareholders' General Meeting of January 30, 2026
Aix-en-Provence, February 2, 2026 - 7:30 a.m. CET - Carvolix (formerly Affluent Medical) (ISIN: FR0013333077 - Ticker:
AFME - "Carvolix" or the "Company"), a French commercial and clinical-stage medical technology company specializing in
the international development and industrialization of breakthrough AI-driven mini-robots and biomimetic implants, to
revolutionize interventional cardiology and the treatment of brain stroke, is today announcing the results of the votes
of its Combined Shareholders' Meeting.
The Combined Shareholders' Meeting was held on Friday January 30, 2026, at 11 a.m. at the registered office of the
Company located 320 avenue Archimède - Les Pleiades III Batiment B -13100 AIX-EN-PROVENCE (France), under the
chairmanship of Mr. Michel Thérin, Chairman of the Board of Directors (the "Board").
The shareholders have adopted the resolution regarding the change of Company's name as well as all the resolutions
supported by the Board, and particularly the delegations granted to the Board related to financial transactions.
The shareholders have also ratified the appointment of Mr. Alain Chevallier as a Board member, and approved the
agreements and commitments referred to in Articles L.225-38 and seq. of the Commercial Code.
Details of the vote results are detailed below:
Number of shares with voting rights 39 350 192
Total number of votes 57 009 926
Number of shareholders present, represented or voting by post 33
Number of shares present, represented or voting by post 35 446 196
Number of votes present, represented or voting by post 52 614 168
Participation rate 92.3 %
For Against Abstain
Extraordinary General Shareholders' Meeting Votes % Votes % Votes %
1. Change of the Company's name; 51 756 98.37% 857 960 1.63% 0 -
208
Delegation of powers to the Board of Directors to
decide, subject to a condition precedent, on a
2. cash capital increase with the removal of 52 614 100.00% 0 0.00% 0 -
preferential subscription rights in favor of named 168
persons, in one or more instalments, for a maximum
nominal amount of EUR1,238,447.00;
3. Removal of preferential subscription rights in 45 655 100.00% 0 0.00% 6 958 -
favor of Truffle BioMedTech Crossover; 421 747
4. Removal of preferential subscription rights in 51 015 100.00% 0 0.00% 1 598 -
favor of Truffle Innov FRR; 787 381
5. Removal of preferential subscription rights in 42 317 100.00% 0 0.00% 10 296 -
favor of Truffle Medeor; 293 875
Delegation of powers to the Board of Directors to
decide, subject to a condition precedent, on a
6. cash capital increase with removal of preferential 52 614 100.00% 0 0.00% 1 -
subscription rights in favor of named persons, on 167
one or more instalments, for a maximum nominal
amount of EUR1,428,398.50;
7. Removal of preferential subscription rights in 45 655 100.00% 0 0.00% 6 958 -
favor of Truffle BioMedTech Crossover; 421 747
8. Removal of preferential subscription rights in 51 015 100.00% 0 0.00% 1 598 -
favor of Truffle Innov FRR; 787 381
9. Removal of preferential subscription rights in 42 317 100.00% 0 0.00% 10 296 -
favor of Truffle Medeor; 293 875
Delegation of authority to the Board of Directors
to decide, subject to a condition precedent, on a 52 614 100.00% 0 0.00% 1 -
10. cash capital increase, in one or more instalments, 167
for a maximum nominal amount of EUR310,730.50;
Removal of preferential subscription rights in 42 317 100.00% 0 0.00% 10 296 -
11. favor of Truffle Medeor; 293 875
Removal of preferential subscription rights in 48 867 100.00% 0 0.00% 3 746 -
12. favor of Financière Memnon; 927 241
Cancellation of preferential subscription rights 52 414 100.00% 0 0.00% 200 001 -
13. in favor of HAYK Holding Sàrl; 167
Removal of preferential subscription rights in 51 568 100.00% 0 0.00% 1 045 -
14. favor of Ginko Invest; 230 938
Removal of preferential subscription rights in 51 756 100.00% 0 0.00% 857 961 -
15. favor of Ms. Simone Merkle; 207
Delegation of powers to the Board of Directors to
decide, subject to a condition precedent, on a
cash capital increase with removal of preferential 52 614 100.00% 0 0.00% 0 -
16. subscription rights in favor of named persons, in 168
one or more instalments, for a maximum nominal
amount of EUR427,350.30;
Removal of preferential subscription rights in 45 655 100.00% 0 0.00% 6 958 -
17. favor of Truffle BioMedTech Crossover; 421 747
Removal of preferential subscription rights in 42 317 100.00% 0 0.00% 10 296 -
18. favor of Truffle Medeor; 293 875
Removal of preferential subscription rights in 48 867 100.00% 0 0.00% 3 746 -
19. favor of Edwards Lifesciences Holding, Inc.; 927 241
Delegation of authority to the Board of Directors
to decide on the issue of shares and/or securities
giving immediate or future access to the share 52 614
20. capital or entitling the holder to a debt 167 100.00% 0 0.00% 1 -
security, with removal of shareholders'
preferential subscription rights in favor of
certain categories of beneficiaries;
Setting of overall limits on the amount of issues 52 614 100.00% 0 0.00% 0 -
21. made pursuant to the delegations granted; 168
Delegation of authority granted to the Board of
Directors to increase the share capital by issuing
ordinary shares or securities giving access to
ordinary shares to be issued immediately or in the
future by the Company, reserved for members of a 3 623 6.89% 48 990 93.11% 1 -
22. company savings plan to be set up by the Company 188 979
under the conditions provided for in Articles
L.3332-18 et seq. of the French Labor Code, with
the removal of shareholders' preferential
subscription rights;
For Against Abstain
Ordinary General Shareholders' Meeting Votes % Votes % Votes %
23. Ratification of the co-optation of Mr Alain 52 614 100.00% 0 0.00% 1 -
Chevallier as member of the Board of Director; 167
Approval of the agreements and commitments referred 30 136 22 477
24. to in Articles L.225-38 et seq. of the Commercial 979 100.00% 0 0.00% 189 -
Code;
25. Power to carry out the legal formalities. 52 614 100.00% 0 0.00% 1 -
167
About Carvolix
Carvolix is a French medical technologies company, commercial and clinical stage, founded by Truffle Capital, that aims to become a global leader in the treatment of structural heart diseases and brain strokes, world's leading causes of mortality and disability. Carvolix develops novel AI and imaging driven mini-robots that make complex procedures doble by interventional cardiologists, as well as biomimetics heart valves..
For more information, please visit www.affluentmedical.com
Contacts:
SEITOSEI.ACTIFIN
CARVOLIX Communication financière / relations presse
Ghislaine GASPARETTO / Enora BUDET
Sébastien Ladet
CEO +33 (0)6 85 36 76 81 / +33 (0)6 72 17 84 60
investor@carvolix.eu
ghislaine.gasparetto@seitosei-actifin.com / enora.budet@seitosei-actifin.com
MC SERVICES AG
PRIMATICE
Relations médias Europe
Relations médias France
Thomas Roborel de Climens Maximilian SCHUR / Julia BITTNER
+33 (0)6 78 12 97 95
+49 (0)211 529252 20 / +49 (0)211 529252 28
thomasdeclimens@primatice.com
affluent@mc-services.eu
----------------------------------------------------------------------------------------------------------------------- Regulatory filing PDF file
File: Carvolix: Results of the votes of the Combined Shareholders' General Meeting of January 30, 2026
=----------------------------------------------------------------------------------------------------------------------
Language: English
Company: Affluent Medical
320 avenue Archimède, Les pléiades III Bâtiment B
13100 Aix en Provence France
France
Phone: +33 4 42 95 12 20
E-mail: jerome.geoffroy@affluentmedical.com
Internet: https://www.affluentmedical.com/
ISIN: FR0013333077
Euronext AFME
Ticker:
AMF Category: Additional regulated information to be pubicly disclosed under the legislation of a Member State / Terms
of availability of the preparatory documents for the GM
EQS News ID: 2269256
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
2269256 02-Feb-2026 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2269256&application_name=news&site_id=dow_jones%7e%7e%7ebed8b539-0373-42bd-8d0e-f3efeec9bbed
(END) Dow Jones Newswires
February 02, 2026 01:30 ET (06:30 GMT)
© 2026 Dow Jones News
